Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2024.2390567DOI Listing

Publication Analysis

Top Keywords

therapies angioimmunoblastic
4
angioimmunoblastic t-cell
4
t-cell lymphoma
4
lymphoma comprehensive
4
comprehensive review
4
review analysis
4
therapies
1
t-cell
1
lymphoma
1
comprehensive
1

Similar Publications

T cell lymphoma constitutes a complex group of diseases, characterized by heterogeneous molecular features and clinical symptoms, and a dismal outcome no matter the therapeutic strategy chosen. In an attempt to improve patients' survival chances, treatment combinations (chemotherapy, radiotherapy, immunotherapy, gene therapy and thermotherapy) have been tested for their synergistic effects that may dramatically improve outcomes and reduce the side effects of each single modality treatment when therapeutic effects add up while side effects are distributed. In this context, nanoscale drug delivery agents have been developed and exploited to enhance the release of drugs in the treatment of several diseases, showing potential benefits in terms of pharmaceutical flexibility, selectivity, dose reduction and minimization of adverse effects.

View Article and Find Full Text PDF

Introduction: Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.

Patients And Methods: We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas.

View Article and Find Full Text PDF

The role of stem cell transplant (auto and allo) in PTCL and CTCL.

Hematology Am Soc Hematol Educ Program

December 2024

Department of Medicine A, University Hospital Muenster, Muenster, Germany.

In contrast to B-cell lymphoma, the advent of modern targeting drugs and immunotherapeutics has not led to major breakthroughs in the treatment of peripheral T-cell lymphoma (PTCL) to date. Therefore, both autologous and allogeneic hematopoietic cell transplantation (HCT) continue to play a central role in the management of PTCL. Focusing on the most common entities (PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, and ALK-negative anaplastic large cell lymphoma), we summarize evidence, indications, and points to consider for transplant strategies in PTCL by treatment line.

View Article and Find Full Text PDF
Article Synopsis
  • Peripheral T-cell lymphoma (PTCL) includes various aggressive subtypes, with the PTCL-NOS and angioimmunoblastic types showing particularly poor responses to standard treatment.
  • Two unique cases illustrate how PTCL can present atypically, with one patient initially misdiagnosed with hip pain and another mistaken for a respiratory infection.
  • Both cases highlight the importance of recognizing constitutional symptoms and conducting thorough imaging to ensure timely diagnosis and treatment, ultimately leading to complete remission after chemotherapy.
View Article and Find Full Text PDF

Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.

Patients And Methods: Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!